Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B

Figure 4 Correlations between viral infection parameters and the frequency of pro-inflammatory cytokine-secreting T cells in chronic hepatitis B patients on nucleoside analogue therapy. The frequency of pro-inflammatory cytokine-secreting T cells increased significantly at treatment weeks 12 and 24. A: Frequency of interleukin-2 positive CD8 T cells (IL-2+ CD8 T); B: Frequency of interferon-gamma positive CD8 T cells (IFN-γ+ CD8 T); C: Frequency of interleukin-17A positive CD4 T cells (IL-17A+ CD4 T); D: Correlation between the hepatitis B envelope antigen (HBeAg) level and the frequency of IL-2+ CD8 T cells; E: Correlation between the HBeAg level and the frequency of IFN-γ+ CD8 T cells; F: Correlation between the HBeAg level and the frequency of IL-17A+ CD4 T cells; G: Correlation between the HBV DNA level and the frequency of IL-2+ CD8 T cells; H: Correlation between the HBV DNA level and the frequency of IFN-γ+CD8 T cells; I: Correlation between the HBV DNA level and the frequency of IL-17A+ CD4 T cells. ^aP < 0.05; ^bP < 0.01.